News | Heart Failure | March 03, 2021

European Union Allows MRI Scans of Heart Failure Patients With Impulse Dynamics Implanted Optimizer Smart Devices

Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

March 3, 2021 — Impulse Dynamics recently announced that DEKRA Certification B.V., a global regulatory organization, approved labeling for the Optimizer Smart device for conditional full-body magnetic resonance imaging (MRI) scans utilizing 1.5 Tesla scanners in the European Union (EU). DEKRA, known for ensuring the safe use of medical devices in global markets, has given heart failure (HF) patients with the Optimizer Smart device implant the opportunity to receive whole-body MRI required to diagnose anatomical and physiological processes.

The commercial significance of this accomplishment affords not only HF patients with peace of mind but healthcare practitioners with unhindered access to perform full-body MRI scans. Additionally, the Optimizer’s safe use approval opens the door to extensive use with other MRI-conditional devices. 

“The MRI full-body certification by DEKRA is a significant step for Impulse Dynamics. This gives patients and physicians the assurance that important diagnostic examinations can be performed for the benefit of patients, independent of the CCM therapy,” said Jens Kalender, vice president of commercial DACH for Impulse Dynamics.

Additionally, Deborah Morley, Ph.D., vice president of regulatory affairs and quality assurance exoplained, “Attainment of whole-body MRI-conditional CE labeling is a major milestone for Impulse Dynamics made possible through positive cooperation with the notified body, DEKRA, and our top-notch engineering team. We look forward to many more such achievements in the near future, advancing CCM therapy to provide hope for heart failure patients worldwide.”

For more information: www.impulse-dynamics.com

Related Content

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

News | EP Lab | July 29, 2021
July 29, 2021 – Results of the STROKE-VT tr...
The devices compared in the study were the Bardy Carnation Ambulatory Monitor long-term continuous ECG system (left) and the BioGuardian MCT cardiac event monitor (right).  #HRS21 #HRS2021 #HeartRhythm21

The devices compared in the study were the Bardy Carnation Ambulatory Monitor long-term continuous ECG system (left) and the BioGuardian MCT cardiac event monitor (right). 

News | EP Lab | July 29, 2021
July 29, 2021 – Results from a new clinical trial find human-oversight dependent continuous electrocardiography (ECG)
St. Jude Medical Pays $27 Million for Allegedly Selling Defective ICD and CRT-D devices
News | EP Lab | July 28, 2021
July 28, 2021 — The U.S. Justice Department announced earlier this month that St. Jude Medical Inc.
Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21
Feature | EP Lab | July 28, 2021
July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of the
The AcQMap 3D Imaging and Mapping System, left, and the AliveCor KardiaMobile device and app for personal ECG monitoring using a smartphone, right. The companies plan to use remote monitoring to see if it helps improve care for ablation patients.

The AcQMap 3D Imaging and Mapping System, left, and the AliveCor KardiaMobile device and app for personal ECG monitoring using a smartphone, right. The companies plan to use remote monitoring to see if it helps improve care for ablation patients.

News | EP Lab | July 27, 2021
July 27, 2021 — AliveCor Inc., which offers FDA-cleared, smart-phone enabled personal electrocardiogram (ECG) technol
Medtronic announced new data from the landmark WRAP-IT study published in Heart Rhythm,[1] demonstrating a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the Tyrx Absorbable Antibacterial Envelope is used at implant. The analysis showed an 82% reduction in major CIED infections among patients with the Tyrx Envelope who developed hematomas compared to patients in the control group who developed hematomas.
News | EP Lab | July 27, 2021
July 27, 2021 — Medtronic announced new data from the landmark WRAP-IT study...
Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

News | EP Lab | June 02, 2021
June 2, 2021 — Implicity, a leader in remote patient monitoring software and cardiac data management solutions, annou
Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

News | EP Lab | May 25, 2021
May 25, 2021 — Acutus Medical Inc.
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Feature | EP Lab | May 16, 2021 | By Dave Fornell, Editor
May 16, 2020 — New data from in the ...